The dopamine precursor L-3,4-dihydroxyphenylalanine (L-DOPA) has been used as an effective drug for treating dopamine depletion-induced Parkinson's disease (PD). However, long-term administration of L-DOPA produces motor complications. L-DOPA has also been found to modify the two key signaling cascades, protein kinase A/dopamine-and cAMPregulated phosphoprotein of 32 kDa (DARPP-32) and extracellular signal-regulated kinases 1 and 2 (ERK1/2), in striatal neurons, which are thought to play a pivotal role in forming motor complications. In the present study, we tested the possible effect of a CB1 cannabinoid receptor agonist on L-DOPA-stimulated abnormal behavioral and signaling responses in vivo. Intermittent L-DOPA administration for 3 weeks induced motor fluctuation in a rat model of PD induced by intrastriatal infusion of dopamine-depleting neurotoxin 6-hydroxydopamine (6-OHDA). A single injection of a CB1 cannabinoid receptor agonist WIN-55,212-2 had no effect on L-DOPA-induced motor fluctuation. However, chronic injections of WIN-55,212-2 significantly attenuated abnormal behavioral responses to L-DOPA in 6-OHDA-lesioned rats. Similarly, chronic injections of WIN-55,212-2 influence the L-DOPA-induced alteration of DARPP-32 and ERK1/2 phosphorylation status in striatal neurons. These data provide evidence for the active involvement of CB1 cannabinoid receptors in the regulation of L-DOPA action during PD therapy.
Introduction
Parkinson's disease (PD) is a neurodegenerative disorder which is characterized by progressive loss of dopaminergic neurons in the substantia nigra. 1 As one of the most common neurological diseases, PD affects approximately 1% of the human population. 2 To relieve dopamine depletion, L-3,4-dihydroxyphenylalanine (L-DOPA), a dopamine precursor, has been used to treat PD and it to date remains the most effective drug for the treatment of PD. 3 However, L-DOPA therapy causes a noticeable side effect. With the progression of the disease, L-DOPA reduces the parkinsonism at the cost of evoking motor complications. 4, 5 In fact, L-DOPA-induced motor complications can become so severely disabling as to negate any clinical benefit from dopaminergic therapy and significant efforts must be made to maintain control of symptoms in the advanced PD patient. Thus, we are forced to find an alternative drug which can reduce L-DOPA-induced motor complications without affecting L-DOPA-induced movements. At this point in time, the pathogenesis of L-DOPA-induced motor complications is not fully understood. Available data from recent studies seem to link distinct plastic changes in striatal neurons to L-DOPA-induced motor complications. 6, 7 In animals showing L-DOPAinduced motor complications after repeated L-DOPA administration, phosphorylation submit your manuscript | www.dovepress.com
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song et al levels of dopamine-and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) and extracellular signal-regulated kinases 1 and 2 (ERK1/2) were increased in striatal neurons. [8] [9] [10] These increases are believed to play a role, and are considered to be characteristic neurochemical changes in the development of L-DOPA-induced motor complications.
Previous studies have reported that the cannabinoid receptor agonist seems to be effective in attenuating L-DOPA-induced dyskinesia in experimental animals and patients, [11] [12] [13] [14] even though precise mechanisms underlying the anti-dyskinetic properties of the cannabinoid receptor agonist are unclear. It has been proposed that cannabinoids may affect psychomotor activity via regulating a signaling cascade in striatal projection neurons involving protein kinase A (PKA)-dependent phosphorylation of DARPP-32. 15 However, the direct effect of the cannabinoid receptor agonist on the L-DOPA-stimulated phosphorylation of ERK1/2 has not been explored at present.
In this study, we attempted to investigate whether pharmacological activation of cannabinoid receptors with a selective agonist alters motor fluctuation induced by repeated injections of L-DOPA during the treatment of PD. A rat model of unilateral 6-hydroxydopamine (6-OHDA)-induced PD was used. In addition to neurobehavioral studies, we tested whether the cannabinoid receptor agonist affects the L-DOPA-associated phosphorylation of the molecular marker (DARPP-32, ERK1/2) in striatal neurons.
Materials and methods animals
Adult Sprague Dawley female rats (180-220 g) were used in this study. Animals were individually housed in clear plastic cages in a controlled environment at a constant temperature of 23°C and humidity of 50%±10% with food and water available ad libitum. The animal room was on a 12/12 hours light/ dark cycle with lights on at 7:00 am. The rats were allowed 6-7 days of habituation to the animal colony before any treatment began. All protocols involving animals were approved by the Institutional Review Board of Xinhua Hospital and were performed according to the guidelines of the National Institutes of Health for the care and use of laboratory animals (NIH publication No 80-23).
Dopaminergic lesions
For creation of the 6-OHDA lesion, the rat was anesthetized with an intraperitoneal (IP) injection of pentobarbital (50 mg/kg). The animal's head was fixed in a stereotactic apparatus (Narishige, Tokyo, Japan). All animals received injections of a total of 8 µg of 6-OHDA (dissolved in 4 µl of 0.9% physiological saline containing 0.02% ascorbic acid [Sigma-Aldrich Co., St Louis, MO, USA]). The coordinates were calculated with reference to bregma for the anterioposterior and the mediolateral coordinates using the rat brain atlas 16 as follows: 1) anterioposterior -3.7, mediolateral -1.7; 2) anterioposterior -4.4, mediolateral -1.2. The dorsoventral position of all injections was -7.8 mm below the dura and the tooth bar set to -2.4 mm. Three weeks after injections, the rats that exhibited a stable apomorphine-induced rotational asymmetry of at least seven full turns per minute away from the lesioned side were selected for the next experiment. It has been previously demonstrated that rats meeting this criterion have a greater than 90% depletion of striatal dopamine. 17 
Treatment
Two experiments were conducted in this work. In the first experiment, the effect of acute IP administration of the CB1 receptor agonist WIN-55,212-2 (Cayman Chemical Company, MI, USA) on L-DOPA-treated rats was evaluated. Fourteen 6-OHDA-lesioned rats were treated with L-DOPA (50 mg/kg plus benserazide 12.5 mg/kg, IP), twice daily for 21 consecutive days. At day 22, fourteen rats were randomly divided into two groups and received co-administration of WIN-55,212-2 (1 mg/kg) or vehicle with L-DOPA (50 mg/kg) and benserazide (12.5 mg/kg). The dose of WIN-55,212-2 (1 mg/kg) was chosen because the agonist at this dose effectively activated the CB1 receptor in vivo. 18 In the second experiment, the effect of chronic administration of WIN-55,212-2 on rats treated with L-DOPA was investigated. Fourteen 6-OHDAlesioned rats were randomly divided into two groups. Animals in the first group were treated with co-administration (IP) of WIN-55,212-2 (1 mg/kg) with L-DOPA (50 mg/kg) and benserazide (12.5 mg/kg) for 21 days. Animals in the second group were treated with co-administration of vehicle with L-DOPA (50 mg/kg) and benserazide (12.5 mg/kg) for 21 days. Seven 6-OHDA-lesioned rats with injections of vehicle for 21 days served as the control.
Behavioral assessment
Rotational behavior was measured immediately after L-DOPA administration at the date indicated (1, 7, 14, 21, and 22 days). The duration of the rotational response was measured as the time between the first 5-minute interval when turning exceeded 20% of the peak rate and the first 5-minute interval when turning fell below 20% of the peak rate. The peak intensity of rotation was measured as the peak number of contralateral turns in any 5-minute interval. 
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Western blot
Animals were deeply anesthetized with pentobarbital (50 mg/kg, IP) and decapitated. Brains were quickly removed and the striatum was dissected. Striatal tissues were homogenized (1:10, weight-to-volume) in a homogenization buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton-100, 1 mM NaF, 100 µM phenylmethylsulfonyl fluoride, and freshly-added protease inhibitor cocktail (Calbiochem, La Jolla, CA, USA). Cytosol fractions were prepared by centrifugation at 12,000× g for 10 minutes at 4°C. Total protein samples (40 µg) were separated on a 10% sodium dodecyl sulphate-polyacrylamide gel and electrophoretically transferred to polyvinylidene difluoride membranes in a Tris-glycine transfer buffer. The membranes were blocked in 5% (weight-to-volume) instant non-fat dried milk for 2 hours at room temperature, and incubated with primary antibodies against DARPP-32 (1:1000), ERK1/2 (1:1000), phospho-DARPP-32 at Thr75 (pDARPP-32; 1:500), phospho-ERK1/2 at Thr202/Tyr204 (pERK1/2, 1:500), β-actin (1:1000), α-tubulin (1:1000) at 4°C overnight. β-actin and α-tubulin were used as a loading control. All antibodies were purchased from Cell Signaling Technology, Inc., (Danvers, MA, USA). The membranes were subsequently washed with tris-buffered saline (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 0.05% Tween 20) and incubated with secondary horseradish peroxidase-conjugated IgG (1:1000) for 1 hour at room temperature. Immunoreactive proteins were visualized by LumiGLO (Cell Signaling Technology, Beverly, MA, USA) chemiluminescent reagent and peroxide. The light-emitting bands were detected with X-ray films. Quantitative analysis of Western blots was performed by calculating the relative density of the immunoreactive bands after acquisition of the blot image with a Nikon charge-coupled device video camera module and analysis with NIH Image (1.34). Values of each band of sample, after background subtraction, are compared with that of β-actin or α-tubulin and expressed as the mean percent of unlesioned striatum for each immunoblot.
statistics
Data are expressed as mean ± standard error of mean. Statistical analysis was conducted by one-way analysis of variance, followed by Dunnett's t-test. A P-value of less than 0.05 was considered statistically significant. Figure 4 effects of chronic administration of Win-55,212-2 on l-DOPa-stimulated ERK1/2 phosphorylation in 6-OHDA-lesioned rats. Notes: Representative Western blots are shown above the quantification of immunoblot results. note that Win-55,212-2 substantially blocked l-DOPastimulated ERK1/2 phosphorylation. In the three groups of 6-OHDA-lesioned rats, daily injections of vehicle, vehicle plus L-DOPA, or WIN-55,212-2 plus L-DOPA were made for 21 days. At day 22, rats were sacrificed and striatal tissue was dissected for immunoblot analysis. Data area expressed as means ± seM (n=6 per group). *P,0.05 versus vehicle; # P,0.05 versus vehicle plus l-DOPa. Abbreviations: 6-OHDA, 6-hydroxydopamine; ERK1/2 extracellular signalregulated kinases 1 and 2; l, lesioned striatum; l-DOPa, l-3,4-dihydroxyphenylala nine; phospho, phosphorylated; seM, standard error of mean; U, unlesioned striatum. In the 6-OHDA-lesioned rat model of PD, chronic L-DOPA administration readily induced motor fluctuation behavior in this study and others. [19] [20] [21] These changes in the motor response are considered as a valid model of the "wearing off" motor fluctuation. 17 L-DOPA-induced dyskinesia is common, but not necessarily present in patients who have developed a "wearing off" response, and, indeed, both motor complications are not believed to originate by the same mechanisms. 22 It has been reported that administration of the cannabinoid agonist can attenuate L-DOPA-induced dyskinesia by assessing axial, limb, and oral abnormal involuntary movements. [11] [12] [13] Our result demonstrated co-administration of the CB1 cannabinoid receptor agonist WIN-55,212-2 ameliorated the motor fluctuation and response failures induced by L-DOPA. In contrast to chronic treatment, acute administration of WIN-55,212-2 had no significant effect on the L-DOPAinduced motor fluctuation. Thus, repeated stimulation of CB1 receptors seems to be needed to render the receptor efficacy in suppressing motor fluctuation.
% of unlesioned side
How CB1 receptors inhibit L-DOPA-induced motor fluctuation is unclear. CB1 receptors are known to be enriched in brain areas important for the regulation of motor activity, including the basal ganglia. 23 The receptor and its endogenous ligand endocannabinoid play a critical role in the modulation of basal ganglia activity. 24, 25 CB1 receptors are also known to co-express with dopamine D1, D2 receptors in the striatum. 23 This co-expression has a functional implication as stimulation of CB1 receptors modified D1, D2-mediated cellular and behavioral responses. 26 Since non-physiological stimulation of dopamine receptors contributes enormously to the development of L-DOPA-induced motor complications, [27] [28] [29] CB1 receptors are believed to counteract with dopamine receptors to antagonize the side effect of L-DOPA. In addition, CB1 receptors are shown to modify striatal glutamatergic and GABAergic activity. 30 Through modifying these systems, CB1 receptors may exert their action.
At the transcriptional level, we found that CB1 stimulation downregulates the phosphorylation of DARPP-32 at Thr75 site, and suppresses the L-DOPA-induced upregulation of ERK phosphorylation. DARPP-32, which is abundantly expressed in the medium spiny neurons of the striatum is one of important downstream effectors of the cAMP/PKA pathway. 31 Its phosphorylation at Thr34 by PKA converts it into an effective inhibitor of protein phosphatase-1, a phosphatase highly expressed in striatal medium spiny neurons. 32, 33 By inhibiting protein phosphatase-1, DARPP-32 increases phosphorylation of distinct signaling proteins important for the regulation of gene expression. In addition to Thr-34, phosphorylation of DARPP-32 at Thr-75 site by cyclindependent kinase 5 blocks PKA-mediated phosphorylation of Thr-34 of DARPP-32, thereby oppositely modulating the efficacy of the PKA signaling cascade. 34 The striatonigral and striatopallidal pathways exert opposing influence on the basal ganglia's control of locomotor function. 35 Therefore, the stimulation of the PKA pathway in striatonigral projecting neurons enhances the locomotor activity, and in striatopallidal projecting neurons acts oppositely. 36 It was reported that the motor depression produced by CP55,940, a CB1 receptor agonist, was reduced by genetic inactivation either of dopamine D2 receptors or of adenosine A 2A receptors. 15 This indicates that a considerable proportion of the psychomotor effect of cannabinoids can be accounted for by a signaling cascade in striatopallidal projecting neurons involving PKA-dependent phosphorylation of DARPP-32, achieved via modulation of dopamine D2 and adenosine A 2A transmission. Therefore, the motor suppression effect induced by co-administration of WIN-55,212-2 may occur through stimulating the PKA pathway in striatopallidal projecting neurons.
Active ERK1/2 have been well documented to be translocated into the nucleus to activate discrete transcription factors such as cAMP-responsive element-binding protein and Elk-1. 37 Active cAMP-responsive element-binding protein and Elk-1 then regulate a program of gene expression to contribute to L-DOPA-induced motor complications. In this study, the CB1 receptor agonist showed the ability to suppress the L-DOPA-stimulated ERK1/2 phosphorylation, but did not normalize the ERK phosphorylation to PD group level. Thus, CB1 receptors may prevent motor fluctuation through a mechanism involving the modulation of the striatonigral and striatopallidal pathway. 
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